论文部分内容阅读
作者报道了一种筛选临床前抗肿瘤药物的新方法。该法用改良后的 Bactec 仪器,通过检测肿瘤细胞代谢~(14)C-葡萄糖而产生的~(14)CO_2的量(标示为“生长指数”),评价药物的细胞毒作用。作者应用该法测定了已进入Ⅰ期或早Ⅱ期临床试验的11种新化合物的抗癌活性,使用的三种人大肠癌细胞系,对已知抗癌药物的体外反应性与临床疗效均呈明显一致性。用90%抑制剂量(ID_(90))与人体血浆峰浓度(PPG)的1/10比值作为实验结果评价标准,凡比值小于30为有效化合物。在所测11种化合物中,有6种已知其 PPC 值,其它化合物
The authors report a new method for screening preclinical antitumor drugs. This method uses a modified Bactec instrument to assess the cytotoxic effect of a drug by measuring the amount of ~ (14) CO_2 (labeled “Growth Index”) produced by the metabolism of ~ (14) C-glucose by tumor cells. The authors used this method to determine the anticancer activity of 11 new compounds that have entered phase I or early phase II clinical trials using three human colorectal cancer cell lines, both in vitro response to known anticancer drugs and in clinical efficacy Conspicuous consistency. The 1/10 ratio of 90% inhibition (ID_ (90)) to human plasma peak concentration (PPG) was used as a criterion for the experimental results, with a ratio of less than 30 as a valid compound. Of the 11 compounds tested, 6 were known for their PPC values and other compounds